288 related articles for article (PubMed ID: 15868931)
1. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
[TBL] [Abstract][Full Text] [Related]
2. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
3. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
4. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
5. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
6. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
7. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
Moelans CB; de Weger RA; van Diest PJ
Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
[TBL] [Abstract][Full Text] [Related]
9. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
10. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?
Sumiyoshi K; Shibayama Y; Akashi S; Nohara T; Iwamoto M; Kobayashi T; Nishimura H; Yoshinaka R; Harada T; Tanigawa N
Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662
[TBL] [Abstract][Full Text] [Related]
11. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
[TBL] [Abstract][Full Text] [Related]
13. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
Shah SS; Wang Y; Tull J; Zhang S
Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
[TBL] [Abstract][Full Text] [Related]
14. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
15. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
16. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
17. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
18. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
Dandachi N; Dietze O; Hauser-Kronberger C
Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
[TBL] [Abstract][Full Text] [Related]
20. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
